Method of preventing acute respiratory viral infections in pre-school children
SUBSTANCE: invention relates to medicine, namely to pediatrics, and concerns prevention of acute respiratory viral infections in pre-school children. For this purpose on the background of vitamin therapy child is prescribed 150 ml of cultured milk product of clinical preventive nutrition bifilact "Biota", mixed with 30 ml of fermenting regenerated live biomass Enterogs with 3-4 weeks course.
EFFECT: said treatment scheme ensures increase of child organism resistance due to efficient correction of intestine disbios by increased concentration of bifidum- and lacto- bacteria with minimal load on fermentative system of gastrointestinal tract.
2 tbl, 2 ex
The present invention relates to medicine, namely to its treatment and prevention field, and can be used in kindergartens, clinics, sanatoria and health resorts, as well as in the home to prevent the occurrence of acute respiratory viral infections in children of preschool age, as well as reduce the severity and shorten the period of recovery in the event of illness.
Children's health is the Foundation that shapes the health of the adult population. Analysis of the health status of preschool children over the last decade shows that the incidence of preschoolers has increased more than twice, and not having deviations in health status declined 3 times. About 70% of children have functional abnormalities and reduced adaptive capacity (group 2 health), and children with chronic diseases (group 3 health) is 14%. In recent years, almost twice reduced the number of children of group 1 health (12%) and in the same time increased the number of children with chronic illnesses. Most children (80%) noted the presence of three or more functional deviations up to 20% of children have abnormalities in physical development mainly due to deficiency of body weight.
In the structure of Zabol the needs of preschool children leading place colds and flu with complicated forms. Highlights a group of sickly children (4 times or more per year).
The greatest number of frequently ill children observed in the younger preschool age, they accounted for 12-30%.
The age of seven years the number of such children is reduced to 5-12%. The incidence is formed mainly due to respiratory diseases.
The first place among respiratory diseases (bronchitis, tonsillitis, pneumonia and others) take ARVI. The marked seasonality in the winter-spring period is about 60% of the average annual cases of all diseases in the year. The emergence and development of this pathology is possible with the increased susceptibility of the organism of the child, the degree of which is determined by the level of nonspecific resistance.
A known way to increase nonspecific resistance in children by hardening of the body of the child (Vroom. "Hygiene of children and adolescents").
The method involves the influence of different physical factors: air baths, hydrotherapy, exercise, rinse nasopharynx, barefoot. In this case, all procedures are carried out periodically within 1-2 months.
Disadvantages: labor intensive method of treatment - the need for hardening in certain artificially created conditions under the constant supervision and with the participation of venture is specially trained staff, often insufficient therapeutic effect.
There is a method of preventing the onset and development of SARS through the use of interferon, passed the closest analogue (Stepanov A.N., The iovlev VI, Smorodintsev AA "Treatment and prevention of leukocyte interferon viral diseases in children". Pediatrics, 1983). The method involves the use of interferon in the premorbid condition or prophylactic instillation of a child in the nasal passages of interferon, diluted in water in a ratio of 1:5 in 1-3 days.
Disadvantages: intolerance, negative side effects (Allergy of the body, the risk of hepatitis and other viral diseases in the case of the use for the manufacture of the drug substandard serum or in case of insufficient sterilization), the relatively high cost of the drug.
Objectives: increase effect preventive effect, the exclusion of side effects, use for preventive purposes natural food with high biological and therapeutic value, lower cost way to prevent colds, the accessibility of the method.
The essence of the invention is the purpose of the child 1-2 times per year on the background of daily vitamin therapy 1-2 times a day in 150 ml of bifractal Biot is", mixed with 30 ml of Enteros, within 3-4 weeks.
In the formation of immune protective factors were important elements of the human intestinal microflora. Inhabiting the gastrointestinal tract of microorganisms performing multiple vital functions. The technical result of the proposed method is to improve the processes of digestion and absorption, intestinal trophism, anti-infective protection, synthesis of vitamins. The result of the use of this method is qualitative and quantitative changes in the composition of intestinal microflora, correction of intestinal dysbiosis, which is a pathological process that generates the reduced resistance of the organism of the whole child.
Revealed a close relationship between the composition of the intestinal microflora and the activity of almost all factors of nonspecific protection, including lysozyme, which have bactericidal and desensitizing effect. Intestinal dysbiosis leads to lymphopenia, hypercortisolism and oppression education lymphoid tissue, which weakens protective-adaptive system of the child's body. Violation of the processes of digestion and absorption when dysbiosis leads to the development of hypovitaminosis.
Thus, correction of the composition of the intestinal microflora has a preventive effect on the child's body - the speed of its growth, vitamin BA is ANS, the efficiency of digestion, resistance to infections.
The proposed use of bifidum and lactobacilli in the composition of bifractal "Biota" native state encourages oppressed segment of the immune system and does not affect the immune system in a normal state.
And in this case the components of the drug microorganisms are identical intestinal flora of man.
Bifilact "Biota" and Anteros mass-produced CJSC PC "Counterservice" since 1995, according to THE 9222-001-34960875-97.
Bifilact "Biota" milk preventive nutrition, prepared on the basis of dry bacterial preparations of Lactobacterin and bifidumbakterin that contribute in the form of Enteros (fermenting regenerated live biomass) in sterile milk. Anteros prepared by serial passages of bacteria on specialized environmentally friendly dairy environments. Anteros is ready to use when the bacteria specific morphological, physiological and biochemical maturity as a result of several regeneration cycles of freeze-dried state, and after mixing them in a certain ratio.
Anteros cultivated in milk, increases the concentration of bifidum and lactobacilli, there is a decomposition of milk protein, the selection of lactic KIS is the notes, enzymes, vitamins, colicins antibiotics of bacterial origin and is formed of the finished milk product that has a pleasant taste, uniform clot and acidity 50-80 Tons
In the process of life lacto - and bifidumbakterin in the finished product compared to the original cow milk content of free amino acids increased by 12-13%, the amount of unsaturated fatty acids increases by 18.6%, casein of milk is processed into promisein, increases the biological value of the finished product and its assimilation.
Bifilact compatible with any drugs, diets and mineral waters, causes no side effects, no contraindications for use. In bevilaqua milk protein is converted by bacteria in such a way that allows you to take it with absolute intolerance to dairy products. Shown to apply starting from 3 days of age. Meets the requirements of SanPiN 2.3.2. 560-96 requirements for baby food. Contains bifidum and lactobacilli in therapeutic concentration (titer of bacteria not below 10/8 in 1 ml of bifractal). One therapeutic dose of Bifidumbacterin and one therapeutic dose of lactobacilli contained in 10 ml of bifractal.
Medicinal properties of bifractal - contains lactic, succinic acid and other acids, which amlawdaily disinfectants, the colicins antibiotics of microbial origin (synthesized lacto - and bifidobacteria), acting antagonistically on pathogenic bacteria (Salmonella, Shigella, Staphylococcus, Streptococcus, Proteus, Klebsiella and others). These components bifractal allow you to start the fight with conditionally pathogenic and pathogenic microflora, to neutralize and remove toxins from the first day of admission bifractal even until stable colonization bifidum and lactobacilli in the gut, and, as a consequence, reduced intake of gamma-globulin in the intestines, stimulates the specific and non-specific immunity. Live bifidum and Lactobacillus found in bevilaqua in therapeutic titles, quickly and steadily colonizing the intestine (2-4 day therapeutic treatment and 10-14 day preventive administration)that normalizes intestinal microflora, have necrotic and regenerating effects on the mucosa of the gastrointestinal tract, stimulates the authors estimated the effect activity of intestinal enzymes, which entails the elimination of the inflammatory process in the small and the large intestines and restores parietal digestion, normalizes the motor function of the intestine, promotes the synthesis of vitamins b, PP, K, D, C, A. Anteros has reinforced the above properties. The concentration of bifidum and lactobacilli, as well the e useful products of their synthesis 2 times higher in Enterarse, than in dairy bevilaqua "Biota".
The method is as follows.
The testing method were formed three groups of children:
1. group - 1 (control) - children who were not conducted any preventive measures.
2. group - 2 control - children who are within 1 months received vitamin therapy (drug, "Vitrum") and Apple juice 150 ml, 2 times a day.
group 3 - experienced children that within 3-4 months received a vitamin and milk bifilact "Biota" 150 ml by adding 30 ml of Enteros 2 times a day as a 2nd Breakfast and afternoon tea. As vitamin therapy used the drug "Vitrum" in therapeutic dosages.
The results of testing are summarized in the tables.
Clinical efficacy of bifractal children.
|Group||The condition of the digestive tract||Improvement of appetite||Bacteriological research||Sleep||ARVI for 3 months|
|1 counter 34 people||Unchanged||Unchanged||Significant is eneny not occurred||Unchanged||75%*|
|2 counter 30 people||+||+||+||+||34%*|
|3 experience 3 8 people||+++||+++||Cm. table.||+++||9, 5%*|
|* - p<0,05|
"+" - improvement
"+++" - a significant improvement
|Bacteriological changes in children as a result of receiving bifractal "Biota"|
|Types of microorganisms||Norma||The examined before treatment||The examined after the treatment|
|E.coli lactose-negative||<105||8×106||not OBN.|
|E. coli hemolytic||0||8%-22%||not OBN.|
|Other opportunistic enterobacteria:||<104|
|Cihobacter greunolii||12×105-8×107||not OBN.|
|Enterobacter agglomerans||14×106||not OBN.|
|Serratia odorigera||4×107||not OBN.|
|Klebiella okyfoca||105||not OBN.|
|Klebsiella pneumoniae||9×104||not OBN.|
|Enterobacter cloacae||31×106||not OBN.|
|Staphylococcus aureus||0||of 1.2×103-3×104||not OBN.|
|Staphylococci (saprophytic, epidermal)||≤104||0||not OBN.|
|Yeast-like fungi of the genus Candida||≤104||0||not OBN.|
|Non-fermentative bacteria||≤104||0||not OBN.|
Example No. 1. Baby K., 4 years. Case history No. 1245. It is registered as a sickly child 5-6 times per year.
Visit the children's educational institution (PEI). In connection with frequent acute respiratory viral infections is not in DOE about 4 months. The child assigned to milk the product "Biota" 150 ml mixed with 30 ml of Enteros 2 times a day for 3 weeks and 1 tablet of the drug "Vitrum" 2 times a day, morning and evening. Treatments conducted in October and in March.
Follow-up care for a child for 3 years (until the end of the term DOE) showed that the baby mild ill SARS total of 3 times. The General condition improved significantly: the baby was sleeping peacefully, differs normal appetite, poise, communication skills.
Example No. 2.
Child Of N., 5 years. Case history No. 1011. Sick almost every month. Visit the children's educational institution (PEI).
As described in example No. 1 scheme child assigned dairy product bifilact "Biota" 150 ml, mixed with 30 ml of Enteros, 1 time a day for 4 weeks and multivitamins "komplivit" 1 tab. in day. The treatment carried out in September and prophylactically in April. The child's condition improved dramatically, normal appetite and sleep, emotional calm. During the year the child was ill ORVI 3 times, in the autumn-spring period in the form of light. Observation for 2 years (before school) characterizes the child's condition as satisfactory: child well physically and mentally developed, SARS does not hurt.
Thus, the use as a prophylactic agent of bifractal "Biota", mixed with 30 planterose, allows you to increase the overall resistance of the body of the child, to avoid side effects of drugs, to exclude contraindications taking into consideration compatibility of receiving fermented milk bifractal "Biota" and Interessa with any food and drug administration.
The method is recommended for wide use in health care practice, in DOE, as well as at home.
The prevention of acute respiratory viral infections in children of preschool age, namely, that the child on the background of vitamin therapy is prescribed 150 ml of fermented milk product of preventive nutrition bifilact "Biota", mixed with 30 ml of Enteros, within 3-4 weeks.
SUBSTANCE: group of inventions concerns biotechnology. Vaccine includes antigen material of avian influenza virus, inactivant and adjuvant. A/Chicken/Novosibirsk/64/05 (H5N1) strain deposited in Russian State Virus Collection of State Institution D.I.Ivanovsky Virology Institute of Russian Medical Science Academy, certificate No 2373, is used as antigen material and reproduced in 9-13 day old chicken embryos and cell cultures in titres of 8.0-10.5 lg EID50/0.2 cm3, with hemagglutination activity of 5-10 log2. For avian influenza prevention bird stock undergoes vaccination by the claimed vaccine injected subcutaneously.
EFFECT: harmless vaccine with high antigen activity.
5 tbl, 5 ex
FIELD: medicine; pharmacology.
SUBSTANCE: invention claims ethers of substituted 1H-indol-3-carboxylic acid of the general formula 1 or their pharmaceutically acceptable salts. Compounds can be applied as active substance for pharmaceutical compositions and for application of these compositions in production of medicine for virus disease prevention and treatment, especially for diseases caused by infection hepatitis viruses (HCV, HBV) and influenza A viruses. In the general formula 1 R1 is aminogroup substitute selected out of hydrogen, optionally substituted inferior alkyl, optionally substituted C3-6cycloalkyl, optionally substituted aryl selected out of phenyl, naphthyl or 5-6 member heteroaryl containing 1-2 heteroatoms selected out of nitrogen, oxygen and sulfur, and possibly condensed with benzene ring of optionally substituted heterocyclyl, which can be optionally substituted 5-6-member heterocyclyl with 1-2 heteroatoms in heterocyclic ring selected out of nitrogen and oxygen; R2 is alkyl substitute selected out of hydrogen, optionally substituted hydroxyl group, optionally substituted mercapto group, optionally substituted arylsulfinyl group; optionally substituted amino group, optionally substituted 5-6-member heterocyclyl containing 1-2 heteroatoms selected out of nitrogen, oxygen and sulfur; R3 is hydrogen or optionally substituted inferior alkyl; R1 4 and R2 4 are independently substitutes of cyclic system, selected out of hydrogen or halogen atom, cyano group, trifluoromethyl, optionally substituted phenyl or optionally substituted heterocyclyl which is an optionally substituted 5-6-member heterocyclyl with 1-2 heteroatoms in heterocyclic ring, selected out of nitrogen, oxygen or sulfur, possibly condensed with benzene ring.
EFFECT: improved efficiency of compositions.
15 cl, 3 tbl, 1 dwg, 6 ex
FIELD: medicine; pediatrics.
SUBSTANCE: administer arbidol in a dose of 50 mg 2 times a week in a combination with active selenium in a dose of 25 mkg on selenium once a day. Duration of prevention - 3-4 weeks.
EFFECT: reduction of frequency and general duration of respiratory infections at the expense of simultaneous correction of disturbances of the immune and metabolic status.
2 tbl, 3 ex
SUBSTANCE: present invention concerns application of new biologically active substances of the general formula of 1 either their racemates, or their optical isomers, or their pharmaceutically comprehensible salts and-or hydrates, and also to a pharmaceutical composition and its use at manufacturing of the medicinal preparations applied to treatment and-or preventive maintenance of diseases, caused by flu viruses. In compounds of the general formula 1, R1 are represented by the substituent to the amino group chosen from unessentially replaced C1-C6alkyl, unessentially replaced aryl or unessentially replaced 5-6 term azaheterocycl, R1 4 and R2 4 independently from each other represent the substituent to an amino group chosen from hydrogen, unessentially replaced C1-C6alkyl, unessentially replaced C3-C8cycloalkyl, or R1 4 and R2 4, together with atom of nitrogen to which they are bound, form through R1 4 and R2 4 unessentially replaced 5-6-term azaheterocycl with 1-3 heteroatoms in a ring and which can be monocyclic or condensed with a benzene ring, or aminoethanamidine; R2 is a substituent chosen from hydrogen, of unessentially replaced mercapto group, unessentially replaced amino group, unessentially replaced hydroxyl represents alkyn; R3 represents the lowest alkyl; R5 the substituent to the cyclic system chosen from hydrogen, atom of halogen, cyano group, unessentially replaced aryl or unessentially replaced 5-6-term heterocycl represents, the containing 1-2 heteroatoms chosen from nitrogen, oxygen or sulphur and which can be monocyclic or condensed with a benzene ring.
EFFECT: invention provides increase of efficiency of a composition and a method of treatment.
11 cl, 1 dwg, 2 tbl, 5 ex
SUBSTANCE: invention relates to application of the substituted esters of 1,2,3,7-tetrahydro-pyrrolo [3,2-f][1,3]benzoxazine-5-carboxylic acid of general formula 1 or their racemoids, or their pharmaceutically acceptable and/or hydrates as substances of pharmaceutical compositions having anti-influenza virus activity: , where: R1 and R4 independently represent amines substitute selected from hydrogen, optionally substituted by liner or branched alkyl, containing 3-12 carbon atoms, optionally substituted cycloalkyl containing 3-10 carbon atoms, optionally substituted aryl, and probably, annelated heterocyclyl, which can be aromatic or non-aromatic and contains from 3 to 10 atoms in the ring, with one or several heteroatoms selected from nitrogen, oxygen or sulphur or their oxides; R2 represents alkyl substitute selected from hydrogen, optionally substituted mercapto group, optionally substituted amino group, optionally substituted hydroxyl; R3 represents lower alkyl; R5 represents substitute of the cyclic system selected from hydrogen, optionally substituted linear or branched alkyl, containing 3-12 carbon atoms, optionally substituted cycloalkyl containing 3-10 carbon atoms optionally substituted aryl or optionally substituted and optionally substituted annelated heterocyclyl, which can be aromatic or non-aromatic and contains from 3 to 10 atoms in the ring with one or several heteroatoms selected from nitrogen, hydrogen or sulphur or their oxides; R6 represents substitute of cyclic system selected from hydrogen, halogen atom, cyano group, optionally substituted aryl or optionally substituted annelated heterocycle, which can be aromatic or non-aromatic and contains from 3 to 10 atoms in the ring with one or several heteroatoms selected from nitrogen, hydrogen or sulphur or their oxides.
EFFECT: production of the pharmaceutical compositions having anti-influenza virus activity.
12 cl, 2 dwg, 2 tbl, 5 ex
SUBSTANCE: invention relates to the new derivative 4-aminomethyl-5-hydroxyindole-3-carboxylate of the general formula I: where; R indicates cyclohexyl, cycloheptyl; R1 indicates C1-C3-alkyl, -CH2-X-phenyl; X indicates NH, O, S; R2 indicates C1-C5-alkyl, R3, R4 have identical value and are selected from C1-C3-alkyl, predominantly, CH3, or R3 and R4 together with a nitrogen atom form -5-10- member heterocycle, which contains 1-2- heteroatom selected from N, O, S or their pharmaceutically acceptable salts, with the exception of 6-bromine-5-hydroxy-4-dimethylaminomethyl-2-phenylthiomethyl-1-cyclohexyl-3-ethoxycarbonylindole, 6-bromine-5-hydroxy-4-dimethylaminomethyl-2-methyl-1-cyclohexyl-3-ethoxycarbonylindole, 6-bromine-5-hydroxy-4-dimethylaminomethyl-2-(piperidinomethyl)-1-cyclohexyl-3-ethoxycarbonylindole, 6-bromine-5-hydroxy-4-dimethylaminomethyl-2-(pirrolidinemethyl)-1-cyclohexyl-3-ethoxycarbonylindole and methyl-1-cyclohexyl-4-piperidinomethyl-6-bromine-5-hydroxy-2-methyl-indole-3-carboxylate. The methods of obtaining compound I are described.
EFFECT: exhibit antiviral activity and can be used for treating influenza of the type A.
5 cl, 2 dwg, 2 tbl, 8 ex
FIELD: organic chemistry, medicine, pharmacy, chemical technology.
SUBSTANCE: invention relates to novel substituted esters of 1,2,3,7-tetrahydropyrrolo[3,2-f][1,3]benzoxazin-5-carboxylic acids of the general formula (1): or their racemates, or their optical isomers, or their pharmaceutically acceptable salts and/or hydrates possessing the antiviral effect. In compounds of the general formula (1) each R1 and R4 represents independently of one another a substitutes of amino group chosen from hydrogen atom, optionally substituted linear or branched alkyl comprising 3-12 carbon atoms, optionally substituted cycloalkyl comprising 3-10 carbon atoms, optionally substituted aryl or optionally substituted and possibly an annelated heterocyclyl that can be aromatic or nonaromatic and comprising from 3 to 10 atoms in ring with one or some heteroatoms chosen from nitrogen, oxygen or sulfur atoms or their oxides; R2 represents alkyl substitute chosen from hydrogen atom, optionally substituted mercapto group, optionally substituted amino group, optionally substituted hydroxyl; R3 represents lower alkyl or cycloalkyl; R5 represents a substitute of cyclic system chosen from hydrogen atom, optionally substituted linear or branched alkyl comprising 3-12 carbon atoms, optionally substituted cycloalkyl comprising 3-10 carbon atoms, optionally substituted aryl or optionally substituted and optionally an annelated heterocyclyl that can be aromatic or nonaromatic and comprising from 3 to 10 atoms in ring with one or some heteroatoms chosen from nitrogen, oxygen or sulfur atoms or their oxides; R6 represents a substitute of cyclic system chosen from hydrogen atom, halogen atom, cyano group, optionally substituted aryl or optionally substituted and optionally annelated heterocyclyl that can be aromatic or nonaromatic and comprising from 3 to 10 atoms in ring with one or some heteroatoms chosen from nitrogen, oxygen or sulfur atoms or their oxides. Also, invention relates to methods for treatment, drugs and pharmaceutical compositions using compounds of this invention. Proposed compounds can be used as active components of drugs used in treatment of such diseases as infectious hepatitis, human immunodeficiency, atypical pneumonia and avian influenza.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition, improved methods of synthesis.
22 cl, 3 tbl, 6 dwg, 7 ex
FIELD: organic chemistry, medicine, pharmacy, chemical technology.
SUBSTANCE: invention relates to novel substituted esters of 1H-indol-3-carboxylic acids of the general formula (1): or their racemates, or their optical isomers, or their pharmaceutical acceptable salts and/or hydrates. Compounds can be used in treatment of such diseases as infectious hepatitis, human immunodeficiency, atypical pneumonia and avian influenza. In compound of the general formula (1) R1, R4 1 and R4 2 each represents independently of one another a substitute of amino group chosen from hydrogen atom, optionally linear or branched alkyl comprising 3-12 carbon atoms, optionally substituted cycloalkyl comprising 3-10 carbon atoms, optionally substituted aryl or optionally substituted and possibly an annelated heterocyclyl that can be aromatic or nonaromatic and comprising from 3 to 10 carbon atom in ring with one or some heteroatoms chosen from nitrogen oxygen or sulfur atoms; or R4 1 and R4 2 in common with nitrogen atom to which they are bound form 5-10-membered azaheterocycle or guanidyl through R4 1 and R4 2; R2 represents an alkyl substitute chosen from hydrogen atom, optionally substituted mercapto group, optionally substituted amino group, optionally substituted hydroxyl; R3 represents lower alkyl; R5 represents a substitute of cyclic system chosen from hydrogen atom, halogen atom, cyano group, optionally substituted aryl or optionally substituted and possibly an annelated heterocycle that can be aromatic or nonaromatic and comprising from 3 to 10 atoms in ring with one or some heteroatoms chosen from nitrogen, oxygen or sulfur atoms. Also, invention relates to methods for treatment, drugs and pharmaceutical compositions using compounds of this invention.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition, improved method of synthesis.
22 cl, 3 tbl, 8 dwg, 6 ex
SUBSTANCE: method involves administering dry inhalation with essential oils in closed room. Eucalyptus and fir oils are used as essential oils. Inhalation is carried out in three stages. The first stage involves applying essential oil of eucalyptus 8 days long with 5 days long inhalation period, 3 days long pause and 3 days long inhalation period. Room saturation with applying essential oil of eucalyptus is started with 5 min a day adding 5 min every following day bringing total inhalation time to 40 min at the eighth day. Eucalyptus oil is applied at a dose of 6 drops per 15 m2. The second stage involves carrying out dry inhalation with two types of essential oils adding inhalation with fir oil. Two days combined inhalation is carried out and then 2 days is pause and 5 days of combined inhalation. Room saturation with fir oil is started with 5 min a day adding 5 min every following day bringing total inhalation time to 35 min at the seventh day. Room saturation with eucalyptus oil is started with 35 min a day subtracting 5 min every following day bringing total inhalation time to 5 min at the seventh day. Saturation with fir oil starts immediately after eucalyptus oil bringing total inhalation time to 40 min per day. Fir oil is used in the amount of 3 drops per 15 m2. The third stage involves carrying out dry inhalation with fir oil only 5 days long. Room saturation with fir oil is started with 40 min a day subtracting 5 min every following day bringing total inhalation time to 20 min at the fifth day.
EFFECT: optimum dose for treating children; improved individual tolerance.
1 dwg, 2 tbl
FIELD: medicine, pharmacy.
SUBSTANCE: invention describes a pharmaceutical composition for its using in treatment of symptoms of catarrhal diseases and influenza, or as an analgesic drug. Composition represents a single dose as an aqueous medicinal formula of the total volume less 100 ml and containing paracetamol and a masking component that attenuates or masks its bitter taste and consisting of at least two components chosen from the following groups (i)-(vi): (i) magnesium chloride, gluconate, hydroxide, carbonate or hydrocarbonate, and/or a mixture of magnesium chloride and magnesium sulfate in the molar ratio from 0.0001:1 to 0.01:1 measured as the ratio magnesium atoms : paracetamol; (ii) gingerin and/or ginger oil in the weight ratio from 1:20000 to 1:10000 with respect to paracetamol; (iii) sweetening agent of the sustained onset effect and prolonged effect chosen from taumatin, neohesperidin DC and/or glycyrrhizin taken in the weight ratio from 1:20000 to 1:100 with respect to paracetamol; (iv) soluble starch taken in the weight ratio from 1:10 to 1:1 with respect to paracetamol; (v) sucrose ester having value of hydrophilic-lipophilic balance (HLB) above 10 and taken in the weight ratio from 1:10 to 2:1 with respect to paracetamol, and (vi) glycine taken in the molar ratio from 1:4 to 2:1 with respect to paracetamol. Proposed composition provides effective taste masking or bitterness of paracetamol being especially in liquid preparations containing less 100 ml of water, and in using the combination of different masking agents also.
EFFECT: improved and valuable properties of composition.
10 cl, 3 tbl, 3 ex
SUBSTANCE: invention relates to medicine, namely to pediatrics and gastroenterology and can be used for treating intestine disbacteriosis in children less than 1 year old. For this purpose bifidumbacterin forte is introduced. First 2-3 days preparation is introduced by 25-30 doses per day in 4 takings. During next 3-4 weeks bifidumbacterin forte is introduced by 5 doses 2 times a day.
EFFECT: method allows increasing efficiency of treatment of disbacteriosis in children less than 1 year old due to application of definite scheme of preparation introduction first in optimally high dose mode, then in supporting doses.
SUBSTANCE: invention concerns medicine, namely to cardiosurgery and can be used as measures on prevention of suppurative and septic complications at cardiac surgery operative measures spent in the conditions of an artificial circulation. For this purpose an antibiotic is entered within the first days after operation. The next days a probiotic is entered. As a probiotic, Sporobacterin preparation in liquid suspension is administered perorally in a dose of 2-5 ml, 2-3 times a day within 7-12 days.
EFFECT: method allows to provide as much as possible effective protection against implications of a surgical infection at the given category of patients at the expense of restoration of anti-infectious resistance to a wide spectrum of contagiums owing to application of the big probiotic doses, and also considerably to lower a medicinal load as a result of unitary introduction of an antibiotic.
3 tbl, 4 ex
FIELD: chemistry; biochemistry.
SUBSTANCE: lactobacillus paracasei CNCM 1-2116 strain is used for preventing or treating neuro-muscular disorders of intestines, caused by infection of intestines by pathogens. Such disorders are associated with, for example, spasmodic pain in the stomach (colic) in infants, pain in the intestines or discomfort in the intestines in general. The Lactobacillus paracasei CNCM 1-2116 strain is used for preventing or treating intestinal complications after infection of intestines by pathogens. The probiotic contains dead bacteria, fermentive substrate and/or material obtained from Lactobacillus paracasei CNCM 1-2116.
EFFECT: achieving beneficial effects due to direct effect on contractibility of muscles.
4 cl, 3 dwg, 2 ex
FIELD: chemistry; biochemistry.
SUBSTANCE: present invention pertains to biotechnology and veterinary science, particularly to methods of drying biological preparations from microbic raw material. The method involves dehydration of Sakhabaktisubtil probiotic using "МИК-2" infrared radiation source at 75°C and 30 minutes exposure.
EFFECT: retention of the lifetime and biological activity of microbial strains, which are the base of the Sakhabaktisubtil germicide.
SUBSTANCE: feed supplement contains bifidobacteria B. bifidum in the form of the bacpreparation Bifidumbacterin - 90 wt % and vegetable supplement - dry powder of stevia leaves and stems - 10 wt %.
EFFECT: normalisation of microbiocenosis caused by malfunction of bifidogenic activity, increasing enzymatic activity and feed assimilability, improving carbohydrate metabolism, increasing productivity characteristics, ensuring ecological health of pigs and environment, increasing feed assimilability, increasing preservation of pig livestock.
5 tbl, 3 ex
SUBSTANCE: feed supplement for sucking piglets containing acidophilic lactic acid bacteria Lb. Acidophilus in the form of feed supplement Biobacton, bifidobacteria B.bifidum in the form of bacpreparation Bifidumbacterin and dry powder of stevia leaves and stems in wt %: feed supplement Biobacton - 18, bacpreparation Bifidumbacterin - 72, dry powder of stevia leaves and stems - 10.
EFFECT: increasing enzymatic activity of piglet gastrointestinal tract, improving carbohydrate metabolism and feed assimilability, normalisation of microbiocenosis caused by malfunction of bifidogenic activity, increasing enzymatic activity, improving productivity characteristics, ensuring ecological health of piglets and environment.
3 tbl, 3 ex
FIELD: medicine; epidemiology.
SUBSTANCE: probiotic drug Vitaflor is administered during 10 days before, on the day of, and 10 days after the vaccination. Before the vaccination Vitaflor is administered perorally as lactobacillus fermented milk, and intranasally as water solution. On the day of, and after the vaccination Vitaflor is administered sublingually as tablets. The invention allows vaccination efficacy increasing due to raising affinity and avidity of antibodies, formed after the vaccination, their prolonged circulation in serum, as well as raising functional activity of phagocytes.
EFFECT: vaccination efficacy increasing.
5 tbl, 1 ex, 2 dwg
FIELD: medicine; biotechnology.
SUBSTANCE: method for metabolic processes intensification in liver consists in peroral administration of composition or preparation, based on Enterococcus faecium M ("ВКПМ" B-3490) and Enterococcus faecium M-3185 ("ВКПМ" B-3491) strains culture; it can be applied, in particular to treatment for: liver impairment, caused by liver disorders and injuries, and manifested by hepatodepressive, cytolytic, and cholestatic syndromes, by intrahepatic portal hypertension; liver regeneration; overstress prevention under impact of extreme environmental factors.
EFFECT: increasing in aerobic productivity of organism, raising lipids proportion in energy supply, and optimising muscle weight to fat weight rate.
5 cl, 6 ex, 4 tbl
FIELD: medicine; urology.
SUBSTANCE: after suppurative focuses surgical sanitation, and complex anti-inflammatory and antibacterial therapy conducting, biovestin is administered beginning from the first postoperative day, 2-3 doses daily 30 minutes before meal. The course lasts for 10 to 14 days.
EFFECT: optimal stimulation of all immune system components in short time due to certain probiotic selection for patient group in question.
1 ex, 2 tbl
SUBSTANCE: method is implemented as follows: bacterial-enzymatic probiotic "Balance-narine-f" is introduced locally and orally in combination with inhalation of negative air ions.
EFFECT: allows for decrease of complications and higher efficiency of treatment.
1 tbl, 3 ex
SUBSTANCE: mare's milk concentrate which has been dried up at temperature from 10 to 50°C at pressure from 1 to 50 mb, on biologically inert, highly dispersive matrix being a highly dispersive dioxide of silicon, apply for obtaining of a preparation for oral ingestion at treatment of diseases of neurodermite and psoriasis. The preparation additionally contains irreplaceable amino acids, hydrocarbonate, potassium, carbonate, citrate, calcium, magnesium, vitamin C, vitamin E, niacin, zinc, iron, beta carotin, pantothenic acid, manganese, vitamin B6, B2, B1, B12, copper, sodium, a biotin, Acidum folicum, molybdenum, selenium, xanthan, fructose, lemon acid, or from both such substances.
EFFECT: application of mare's milk concentrate is oral for neurodermite and psoriasis treatment, firmness at storage and maintenance of high-quality components in the concentrated form.
6 cl, 7 tbl, 6 ex